Largest biotech companies by total assets
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech companies ranked by total assets, at AED 332.7B, ahead of Gilead Sciences (AED 216.8B) and Biogen (AED 108.1B). Figures as of 18 Nov 2026, 18:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenAED 332.7B
- Median
- AED 9.4B
- Combined market value
- AED 3.09T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | AED 332.7B | AED 886.8B | AED 1,639.55 | 2.52% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | AED 216.8B | AED 769.9B | AED 620.76 | 0.73% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | AED 108.1B | AED 136.9B | AED 925.97 | 0.53% up | 49% up | ||
| 4 | BioNTechBNTX · Health Care | AED 89.6B | AED 76.4B | AED 308.12 | 1.14% down | 16% down | ||
| 5 | ModernaMRNA · Health Care | AED 45.3B | AED 296.8B | AED 733.61 | 3.42% down | 755% up | ||
| 6 | argenxARGX · Health Care | AED 31.9B | AED 218.7B | AED 3,478.00 | 0.06% down | 4% up | ||
| 7 | QiagenQGEN · Health Care | AED 23.1B | AED 37.7B | AED 182.54 | 0.10% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | AED 17B | AED 61B | AED 602.25 | 1.18% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | AED 11B | AED 34.1B | AED 215.65 | 1.15% down | 22% up | ||
| 10 | RepligenRGEN · Health Care | AED 10.8B | AED 40.7B | AED 636.88 | 6.92% up | 5% up | ||
| 11 | ExelixisEXEL · Health Care | AED 10.4B | AED 61.9B | AED 253.50 | 0.76% up | 63% up | ||
| 12 | Bio-TechneTECH · Health Care | AED 9.5B | AED 42B | AED 267.41 | 0.24% up | 26% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | AED 9.3B | AED 40.3B | AED 353.88 | 0.40% up | 37% up | ||
| 14 | Revolution MedicinesRVMD · Health Care | AED 8.6B | AED 127.6B | AED 589.76 | 1.30% down | 131% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | AED 8.3B | AED 14.8B | AED 152.26 | 3.25% up | 21% down | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | AED 6.4B | AED 38.3B | AED 448.46 | 0.48% up | 87% up | ||
| 17 | Krystal BiotechKRYS · Health Care | AED 4.9B | AED 34.3B | AED 1,158.14 | 5.62% up | 46% up | ||
| 18 | ImmunovantIMVT · Health Care | AED 3.5B | AED 25.4B | AED 122.93 | 0.78% up | 43% up | ||
| 19 | CG OncologyCGON · Health Care | AED 2.9B | AED 26.3B | AED 294.68 | 1.63% up | 85% up | ||
| 20 | Twist BioscienceTWST · Health Care | AED 2.4B | AED 29.7B | AED 434.91 | 5.72% up | 340% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | AED 1.9B | AED 17.1B | AED 105.76 | 1.07% up | 88% up | ||
| 22 | ImmunityBioIBRX · Health Care | AED 1.8B | AED 26.2B | AED 24.66 | 7.27% up | 193% up | ||
| 23 | Scholar Rock HoldingSRRK · Health Care | AED 1.5B | AED 21.3B | AED 174.72 | 5.52% up | 14% up | ||
| 24 | Kodiak SciencesKOD · Health Care | AED 1.3B | AED 23.2B | AED 355.24 | 0.08% down | 396% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6729 AED).
Questions and answers
Which biotech companies rank first by total assets?
Amgen (AED 332.7B), Gilead Sciences (AED 216.8B) and Biogen (AED 108.1B) are the top three of the 24 biotech companies ranked by total assets as of 18 Nov 2026, 18:41 UTC.
How many biotech companies are in this ranking?
24 are ranked by total assets.
What are these biotech companies worth together?
The 24 biotech companies ranked by total assets have a combined market value of AED 3.09T as of 18 Nov 2026, 18:41 UTC.
What does ranking by total assets measure?
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by total assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-assets
Underlying data: Yahoo Finance; SEC EDGAR.